ClinicalTrials.gg
Not yet recruitingNCT07937176Updated Nov 13, 2026

Clinical Evaluation of SHOFU FX-LC RMGI Restoration Versus FUJI II RGMI in Management of Anterior Carious Cervical Lesions

An interventional study of SHOFU GlasIonomer FX-LC and FUJI II RMGI in Carious Anterior Class V, sponsored by Cairo University. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The development of resin-modified glass ionomers (RMGIs) represents a strategic evolution designed to augment the mechanical performance of conventional glass ionomers. By incorporating a resin matrix, these materials achieve notable physical improvements, including superior fracture toughness, increased resistance to occlusal wear, and higher resilience to moisture degradation, alongside the clinical advantage of a prolonged working time. (Hübel 2003)However, an excessive proportion of hydrophobic multifunctional monomers within the RMGI matrix suppresses the essential aqueous acid-base reaction.

To overcome conventional resin modified glass ionomer drawbacks, FX-LC tried to overcome it by incorporating a new multifunctional acrylamide monomer called New Generation Acrylamide monomer (NGA monomer) with which they claim that it exhibits high water solubility due to its four amide bonds (-CO-NH-) and demonstrates high polymerization reactivity, even in the presence of water. It has unique properties that are not found in conventional multifunctional monomers

02

Conditions studied

  • Carious Anterior Class V

Keywords

  • FX-LC
  • Acrylamide
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,951 studies on the registry; 1,463 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient inclusion:

    1. Adult Patients age >18 years.
    2. Males or Females
    3. Patients with good likelihood of recall availability.

Tooth inclusion:

  1. Permanent anterior teeth with cervical Class V, carious lesions (ICDAS 3-5)
  2. Vital and with positive reaction to cold stimulus.
  3. Well-formed and fully erupted teeth.

Exclusion criteria

Exclusion Criteria:

  • Patient exclusion:

    1. Participants with general/systemic illness.
    2. Pregnant or lactating females.
    3. Concomitant participation in another research study.
    4. Inability to comply with study procedures.
    5. Heavy Bruxism Habits.
    6. Last experience with allergic reactions against any components of the used materials.
    7. Patients receiving orthodontic treatment.

Tooth exclusion:

  1. Teeth with clinical symptoms of pulpitis such as spontaneous pain or sensitivity to pressure.
  2. Non-vital teeth, Fractured or cracked teeth.
  3. Secondary carious lesions.
  4. Hypocalcified or hypoplastic teeth
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    SHOFU FX-LC RMGI

    After rubber dam isolation, the prepared cavities will be conditioned using Dentin conditioner (GlasIonomer FX-LC Conditioner, Japan) 10-20% polyacrylic acid for 20 seconds then will be rinsed with copious amount of water for 15 seconds and dried with oil free compressed air for 5 seconds till the surface had a matte shiny appearance. The (SHOFU FX- LC) capsule will be inserted into a high-speed amalgamator (Mix 2000, Carlo De Giorgi, Milano, Italy) and triturated for 10 seconds. The mixture then is extruded directly out of capsule into prepared cavities with a capsule gun ensuring that no air bubbles will be included.

    Other: SHOFU GlasIonomer FX-LC

  • Active comparator
    FUJI II RMGI

    Cavities will be conditioned using using Dentin conditioner (GC Dentine ConditionerS) 10-20% polyacrylic acid for 20 seconds then will be rinsed with copious amount of water for 15 seconds and dried with oil free compressed air for 5 seconds till the surface had a matte shiny appearance. The (Fuji II LC) capsule will be inserted into a high-speed amalgamator (Mix 2000, Carlo De Giorgi, Milano, Italy) and triturated for 10 seconds. The mixture then is extruded directly out of capsule into prepared cavity with a capsule gun ensuring that no air bubbles will be included. light curing unit will be used to cure the material for 20 seconds with a visible light unit at 470 nm, holding the light as close to the surface as possible, according to manufacturer instruction.

    Other: FUJI II RMGI

Interventions

  • OtherSHOFU GlasIonomer FX-LC

    FX-LC is RMGI which incorporates New Generation Acrylamide monomer, After rubber dam isolation, the prepared cavities will be conditioned using Dentin conditioner (GlasIonomer FX-LC Conditioner, Japan) 10-20% polyacrylic acid for 20 seconds then will be rinsed with copious amount of water for 15 seconds and dried with oil free compressed air for 5 seconds till the surface had a matte shiny appearance. The (SHOFU FX- LC) capsule will be inserted into a high-speed amalgamator (Mix 2000, Carlo De Giorgi, Milano, Italy) and triturated for 10 seconds. The mixture then is extruded directly out of capsule into prepared cavities with a capsule gun ensuring that no air bubbles will be included. Light curing unit will be used to cure the material for 10 seconds with a visible light unit at 470 nm, holding the light as close to the surface as possible, according to manufacturer instruction.

  • OtherFUJI II RMGI

    FUJI II, Conventional resin modifies glass ionomer will bwe applied. Cavities will be conditioned using using Dentin conditioner (GC Dentine ConditionerS) 10-20% polyacrylic acid for 20 seconds then will be rinsed with copious amount of water for 15 seconds and dried with oil free compressed air for 5 seconds till the surface had a matte shiny appearance. The (Fuji II LC) capsule will be inserted into a high-speed amalgamator (Mix 2000, Carlo De Giorgi, Milano, Italy) and triturated for 10 seconds. The mixture then is extruded directly out of capsule into prepared cavity with a capsule gun ensuring that no air bubbles will be included. light curing unit will be used to cure the material for 20 seconds with a visible light unit at 470 nm, holding the light as close to the surface as possible, according to manufacturer instruction.

06

What researchers measure

Primary outcomes

  1. Clinical Performance assessing Biological, Mechanical and Esthetic Parameters Using Modified USPHS Criteria

    Time frame: Time Frame: Baseline, 6 months, 12 months, 18 months.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2028, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 8, 2026
First posted
Nov 13, 2026
StartEst.
Nov 2026
Primary completionEst.
Mar 2028
CompletionEst.
May 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937176
Lead sponsor
Cairo University
Responsible party
Salma Hany Mohamed Saeed (BDS 2022, New Giza University., Cairo University) — Principal investigator
First posted
Nov 13, 2026
Start date
Nov 2026 (estimated)
Primary completion
Mar 2028 (estimated)
Completion
May 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Salma hany Nadeem, BDS 2022
Contact
salma.hany@dentistry.cu.edu.eg
(+2)01033719904

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion